Standard

Transfusion-related acute lung injury: a clinical review. / Vlaar, Alexander P. J.; Juffermans, Nicole P.

In: Lancet, Vol. 382, No. 9896, 2013, p. 984-994.

Research output: Contribution to journalReview articleAcademicpeer-review

Harvard

APA

Vancouver

Author

BibTeX

@article{87d77e5308854d29a71eca5bfdf45fe1,
title = "Transfusion-related acute lung injury: a clinical review",
abstract = "Three decades ago, transfusion-related acute lung injury (TRALI) was considered a rare complication of transfusion medicine. Nowadays, the US Food and Drug Administration acknowledge the syndrome as the leading cause of transfusion-related mortality. Understanding of the pathogenesis of TRALI has resulted in the design of preventive strategies from a blood-bank perspective. A major breakthrough in efforts to reduce the incidence of TRALI has been to exclude female donors of products with high plasma volume, resulting in a decrease of roughly two-thirds in incidence. However, this strategy has not completely eradicated the complication. In the past few years, research has identified patient-related risk factors for the onset of TRALI, which have empowered physicians to take an individualised approach to patients who need transfusion",
author = "Vlaar, {Alexander P. J.} and Juffermans, {Nicole P.}",
year = "2013",
doi = "10.1016/S0140-6736(12)62197-7",
language = "English",
volume = "382",
pages = "984--994",
journal = "Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9896",

}

RIS

TY - JOUR

T1 - Transfusion-related acute lung injury: a clinical review

AU - Vlaar, Alexander P. J.

AU - Juffermans, Nicole P.

PY - 2013

Y1 - 2013

N2 - Three decades ago, transfusion-related acute lung injury (TRALI) was considered a rare complication of transfusion medicine. Nowadays, the US Food and Drug Administration acknowledge the syndrome as the leading cause of transfusion-related mortality. Understanding of the pathogenesis of TRALI has resulted in the design of preventive strategies from a blood-bank perspective. A major breakthrough in efforts to reduce the incidence of TRALI has been to exclude female donors of products with high plasma volume, resulting in a decrease of roughly two-thirds in incidence. However, this strategy has not completely eradicated the complication. In the past few years, research has identified patient-related risk factors for the onset of TRALI, which have empowered physicians to take an individualised approach to patients who need transfusion

AB - Three decades ago, transfusion-related acute lung injury (TRALI) was considered a rare complication of transfusion medicine. Nowadays, the US Food and Drug Administration acknowledge the syndrome as the leading cause of transfusion-related mortality. Understanding of the pathogenesis of TRALI has resulted in the design of preventive strategies from a blood-bank perspective. A major breakthrough in efforts to reduce the incidence of TRALI has been to exclude female donors of products with high plasma volume, resulting in a decrease of roughly two-thirds in incidence. However, this strategy has not completely eradicated the complication. In the past few years, research has identified patient-related risk factors for the onset of TRALI, which have empowered physicians to take an individualised approach to patients who need transfusion

U2 - 10.1016/S0140-6736(12)62197-7

DO - 10.1016/S0140-6736(12)62197-7

M3 - Review article

C2 - 23642914

VL - 382

SP - 984

EP - 994

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 9896

ER -

ID: 2132363